Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTION phase 3 trial of lixivaptan in autosomal dominant polycystic kidney disease
MOH_2022-01-03_010514Phase 3Not yet recruiting
- Sponsor
- Palladio Biosciences
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Lixivaptan with Placebo (2 arms). Primary endpoint: Difference in eGFR between lixivaptan and placebo in Part 1. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
lixivaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on MOH_2022-01-03_010514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-01-03_010514.